Cargando…
How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience
BACKGROUND: Hepatocellular carcinoma is a relevant cause of mortality worldwide, mainly among patients who have a prior liver disease. In spite of clear recommendations regarding surveillance and screening methods, most patients are still diagnosed only when they are no longer candidates to curative...
Autores principales: | Kawanami, Gustavo Hideki, Katsuda, Leopoldo, Rocha, Thiara Barcelos, da Silva Yamashiro, Fabio, Pelafsky, Leonardo, Qi, Xingshun, Romeiro, Fernando Gomes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878098/ https://www.ncbi.nlm.nih.gov/pubmed/33614533 http://dx.doi.org/10.1155/2021/6219896 |
Ejemplares similares
-
Autodialysis in Morocco: how much longer can we wait?
por: Noto-Kadou-Kaza, Béfa, et al.
Publicado: (2019) -
Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023) -
Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021) -
Who Should Pay for Global Health, and How Much?
por: Carrasco, Luis R., et al.
Publicado: (2013) -
How Much Orthodontia Should the General Practitioner Do?
por: Dewey, Martin
Publicado: (1905)